BioInvent to Supply Critical Antibodies for Orbus Medical Technology´s Innovative Genous Bio-engineered Surface

25-Jun-2004

Lund, Sweden and Fort Lauderdale, FL, USA: BioInvent International AB and Orbus Medical Technologies, Inc. announced the signing of an agreement for the supply of cGMP quality antibodies for clinical evaluation stents coated with the Genous Bio-engineered Surface. This innovative coating is applied to a stent for the prevention of thrombosis (blood clotting) and the reduction of restenosis (reblockage) following coronary angioplasty to open clogged arteries. Uncoated bare metal stents can result in reblockages in approximately one out of four procedures. The antibodies are the main component of the stent surface coating that actively recruits a patient´s own endothelial cells to heal the area where the stent has been placed.

Following successful process development at BioInvent and product approval, Orbus intends to enter into a long term supply agreement for the commercial grade antibody with BioInvent. Commenting on the deal Svein Mathisen, CEO of BioInvent, said, "we are pleased to be able to support the final stages of Orbus´ innovative product development as well as offer long term supply of the key component. We see this agreement as another brick in the implementation of our CMO strategy. We are confident that our efforts to improve our manufacturing capabilities and activities from development to commercial scale are benefiting our clients as well as our own projects."

Orbus´ Vice President of Operations and Finance, Wayne Johnson, commented, "this technology is of critical importance to our future as a company and we obviously need a reliable, secure business partner for the supply of the antibodies. We are comfortable that BioInvent meets these criteria and look forward to establishing a long-term relationship."

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous